Department of Nuclear Medicine, Sheba Medical Center, Ramat Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Acta Haematol. 2022;145(3):267-274. doi: 10.1159/000522323. Epub 2022 Jan 31.
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulted in changes in management and imaging routines for patients with hematological malignancies. Treating physicians had to familiarize themselves with a new disease, with distinct imaging manifestations, sometimes overlapping with other infections prevalent in this patient population. In some aspects, infected hematological patients might exhibit a different disease course, and routine imaging in asymptomatic hematological patients may result in unexpected COVID-19 findings, implying covert infection, that should be further explored. Furthermore, some complications of hematological diseases and treatments may present with findings similar to COVID-19 manifestations, and treating physicians must consider both possibilities in the differential diagnosis. In this review, we aimed to present the influence the COVID-19 pandemic had on hematological malignancy imaging.
由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 COVID-19 大流行导致血液系统恶性肿瘤患者的管理和影像学常规发生了变化。治疗医生必须熟悉一种新疾病,这种疾病具有独特的影像学表现,有时与该患者人群中流行的其他感染重叠。在某些方面,感染的血液系统患者可能表现出不同的疾病过程,而无症状血液系统患者的常规影像学检查可能会发现意想不到的 COVID-19 结果,提示隐匿性感染,应进一步探索。此外,血液系统疾病和治疗的一些并发症可能表现出与 COVID-19 表现相似的结果,治疗医生在鉴别诊断时必须考虑这两种可能性。在这篇综述中,我们旨在介绍 COVID-19 大流行对血液系统恶性肿瘤影像学的影响。